PDF(Pubmed)
Abstract：
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer with a poor prognosis. Recently, an immunotherapy strategy represented by programmed cell death 1 (PD-1) inhibitors has been applied to the systemic treatment of advanced iCCA. However, immunotherapy combined with chemotherapy as first-line maintenance therapy was rarely reported. Our report presented an advanced iCCA patient who had a dramatic response to the PD-1 inhibitor sintilimab combined with gemcitabine plus cisplatin as the first-line therapy and sintilimab combined with capecitabine as maintenance therapy, yielding an ongoing progression-free survival of 16 months.
摘要：
肝内胆管癌（iCCA）是第二常见的原发性肝癌，预后不良。最近,以程序性细胞死亡1(PD-1)抑制剂为代表的免疫治疗策略已应用于晚期iCCA的全身治疗.然而,免疫治疗联合化疗作为一线维持治疗的报道很少.我们的报告介绍了一名晚期iCCA患者，该患者对PD-1抑制剂sintilimab联合吉西他滨加顺铂作为一线治疗和sintilimab联合卡培他滨作为维持治疗有戏剧性反应。产生16个月的持续无进展生存期。
